T_{reg} deficiency-mediated T_{H1} response causes human premature ovarian insufficiency through apoptosis and steroidogenesis dysfunction of granulosa cells

Xue Jiao^{1,2,3,4,\#} | Xiruo Zhang^{1,3,4,\#} | Nianyu Li^{1,3,4} | Dunfang Zhang^{2} | Shidou Zhao^{1,3,4} | Yujie Dang^{1,3,4} | Peter Zanvit^{2} | Wenwen Jin^{2} | Zi-Jiang Chen^{1,3,4,5,6} | Wanjun Chen^{2} | Yingying Qin^{1,3,4} 

1 Center for Reproductive Medicine, Cheeilo College of Medicine, Shandong University, Jinan, Shandong, China
2 Mucosal Immunology Section, NIDCR, National Institutes of Health, Bethesda, Maryland, USA
3 National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Shandong University, Jinan, Shandong, China
4 Key laboratory of Reproductive Endocrinology of Ministry of Education, Shandong University, Jinan, Shandong, China
5 Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China
6 Center for Reproductive Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Correspondence
Zi-Jiang Chen, Center for Reproductive Medicine, Cheeilo College of Medicine, Shandong University, No.157, Jinglulu Road, Jinan 250021, China. Email: chenzijiang@hotmail.com
Wanjun Chen, Mucosal Immunology Section, NIDCR, NIH, 30 Convent Dr., Bethesda, Maryland 20892, USA. Email: wchen@dir.nidcr.nih.gov

Graphical Abstract
The Treg cells deficiency with decreased number and impaired suppression function mediate augmented T_{H1} responses in premature ovarian insufficiency (POI).
Yingying Qin, Center for Reproductive Medicine, Cheeloo College of Medicine, Shandong University, No.157, Jingliu Road, Jinan 250021, China. Email: qinyingying1006@163.com

HIGHLIGHTS

- Deficient Treg cells fail to restrain augmented TH1 response in POI patients.
- The increased ratio of TH1: Treg cells correlates with severity of POI.
- Treg cells prevent and reverse TH1-mediated ovarian insufficiency in mice.
- TH1 cytokines impair GCs growth and steroidogenesis by modulating CTGF and CYP19A1.

The increased TH1 proinflammatory cytokines IFN-γ and TNF-α impair steroidogenesis by targeting CYP19A1 and promote apoptosis of granulosa cells partially by down-regulation of CTGF via JAK-STAT1 and NF-κB activation, hence contribute to follicle atresia, ovarian dysfunction and premature insufficiency.
T<sub>reg</sub> deficiency-mediated T<sub>H1</sub> response causes human premature ovarian insufficiency through apoptosis and steroidogenesis dysfunction of granulosa cells

Xue Jiao<sup>1,2,3,4,#</sup> | Xiruo Zhang<sup>1,3,4,#</sup> | Nianyu Li<sup>1,3,4</sup> | Dunfang Zhang<sup>2</sup>

Shidou Zhao<sup>1,3,4</sup> | Yujie Dang<sup>1,3,4</sup> | Peter Zanvit<sup>2</sup> | Wenwen Jin<sup>2</sup>

Zi-Jiang Chen<sup>1,3,4,5,6</sup> | Wanjun Chen<sup>2</sup> | Yingying Qin<sup>1,3,4</sup><sup>6</sup>

1 Center for Reproductive Medicine, Cheeolo College of Medicine, Shandong University, Jinan, Shandong, China
2 Mucosal Immunology Section, NIDCR, National Institutes of Health, Bethesda, Maryland, USA
3 National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Shandong University, Jinan, Shandong, China
4 Key laboratory of Reproductive Endocrinology of Ministry of Education, Shandong University, Jinan, Shandong, China
5 Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China
6 Center for Reproductive Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Correspondence
Zi-Jiang Chen, Center for Reproductive Medicine, Cheeolo College of Medicine, Shandong University, No.157, Jingliu Road, Jinan 250021, China.
Email: chenzijiang@hotmail.com
Wanjun Chen, Mucosal Immunology Section, NIDCR, NIH, 30 Convent Dr., Bethesda, Maryland 20892, USA.
Email: wchen@dir.nidcr.nih.gov
Yingying Qin, Center for Reproductive Medicine, Cheeolo College of Medicine, Shandong University, No.157, Jingliu Road, Jinan 250021, China.
Email: qinyingying1006@163.com

#These authors contributed equally

Abstract
Immune dysregulation has long been proposed as a component of premature ovarian insufficiency (POI), but the underlying mediators and mechanisms remain largely unknown. Here we showed that patients with POI had augmented T helper 1 (T<sub>H1</sub>) responses and regulatory T (T<sub>reg</sub>) cell deficiency in both the periphery and the ovary compared to the control women. The increased ratio of T<sub>H1</sub>:T<sub>reg</sub> cells was strongly correlated with the severity of POI. In mouse models of POI, the increased infiltration of T<sub>H1</sub> cells in the ovary resulted in follicle atresia and ovarian insufficiency, which could be prevented and reversed by T<sub>reg</sub> cells. Importantly, interferon (IFN)-γ and tumor necrosis factor (TNF) -α cooperatively promoted the apoptosis of granulosa cells and suppressed their steroidogenesis by modulating CTGF and CYP19A1. We have thus revealed a previously unrecognized T<sub>reg</sub> cell deficiency-mediated T<sub>H1</sub> response in the pathogenesis of POI, which should have implications for therapeutic interventions in patients with POI.

List of Abbreviations: bPOI, biochemical POI; CTGF, connective tissue growth factor; CYP19A1, cytochrome P450 family 19 subfamily A member 1; E<sub>2</sub>, estradiol; FOXO1, forkhead transcription factor; FSH, follicle-stimulating hormone; GATA6, GATA binding protein 6; GCs, granulosa cells; IFN-γ, interferon-γ; IL-10, interleukin-10; INHBA, inhibin beta A; JAK/ STAT1, janus kinase /signal transducer, activator of transcription 1; MFI, mean fluorescence intensity; NF-κB, nuclear factor kappa-B; PBMCs, peripheral blood mononuclear cells; POI, premature ovarian insufficiency; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; T, testosterone; TGF-β1, transforming growth factor-β1; T<sub>H1</sub>, T helper 1; TNF-α, tumor necrosis factor-α; T<sub>reg</sub>, regulatory T cells; WT1, Wilms’ tumor gene

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics

Clin. Transl. Med. 2021;11:e448.
https://doi.org/10.1002/ctm2.448
1 | INTRODUCTION

Infertility has increasingly become a public health burden worldwide (~10%–15%). Premature ovarian insufficiency (POI) is one of the most common causes of female infertility given its inherent feature of compromised reproduction. The disorder is characterized by cessation of ovarian function before the age of 40 years and increased risks of osteoporosis and cardiovascular disease.\(^1,2\) POI occurs as a continuum of ovarian function decline with progressive menstrual irregularity or amenorrhea, elevated follicle-stimulating hormone (FSH), and reduced estradiol (E\(_2\)).\(^3\) It is estimated to affect 1%–5% of reproductive-aged women. It can result from a small pool of primordial follicles, follicle dysfunction, and premature follicle depletion due to accelerated atresia. POI is highly heterogeneous in etiology, and the majority remains to be elucidated.\(^4,5\)

An autoimmune origin has long been considered to explain 5%–30% of POI cases.\(^6–8\) POI is often associated with concomitant autoimmune diseases, including autoimmune thyroiditis, psoriasis, type 1 diabetes, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA).\(^6,9\) POI can also be one component of autoimmune polyendocrinopathy syndrome due to AIRE mutations.\(^10,11\) The presence of oophoritis and circulating autoantibodies has been reported in a subset of women with POI, especially patients with autoimmune adrenal insufficiency.\(^8,12,13\) Reliable and specific diagnostic markers for autoimmune POI, however, are lacking in the clinic. The mechanisms of autoimmune disturbance underlying ovarian senescence are largely unknown.

Adaptive immune responses are tailored to different types of pathogens through differentiation of naïve CD4\(^+\) T cells into functionally distinct subsets of effector T cells (T helper 1 [T\(_{H1}\)], T\(_{H2}\), and T\(_{H17}\)). CD4\(^+\)Foxp3\(^+\) regulatory T (T\(_{reg}\)) cells comprise a distinct suppressive lineage and play crucial roles in peripheral immune tolerance.\(^14\) T\(_{reg}\) cell suppressive function can be achieved by direct cell contact through coinhibitory molecules such as CTLA-4 and the production of immune regulatory cytokines such as transforming growth factor-\(\beta\) (TGF-\(\beta\)) and interleukin-10 (IL-10).\(^15,16\) The balance between pro- and anti-inflammatory subsets is finely tuned to maintain immune homeostasis. Quantitative and functional dysregulation of T\(_{reg}\) cells or augmented autoreactive response of inflammatory effector T cells underlies the autoimmunity and tissue damage in multiple autoimmune diseases, such as multiple sclerosis, SLE, and RA.\(^14\) Whether the altered pathogenic T subsets and cytokines, if any, are implicated in the disruption of ovarian microenvironment homeostasis and contribute to the pathogenesis of human POI remain poorly defined.

In this study, we have comprehensively characterized the autoimmune disturbances in patients with POI and demonstrated the augmented T\(_{H1}\) autoimmunity and T\(_{reg}\) cell deficiency both in the periphery and ovarian microenvironment in POI patients. The decreased ratio of T\(_{reg}\) to T\(_{H1}\) cells strongly correlated with the severity of POI disease. In experimental POI models in mice, we elucidated the causative role of T\(_{H1}\) cells in ovarian damage, which was prevented and suppressed by T\(_{reg}\) cells. Importantly, we determined that T\(_{H1}\) cytokines interferon (IFN)-\(\gamma\) and tumor necrosis factor (TNF)-\(\alpha\) directly promoted apoptosis and inhibited the proliferation and steroidogenesis of human granulosa cells (GCs) \textit{in vitro} by downregulating the connective tissue growth factor (CTGF) and cytochrome P450 family 19 subfamily A member 1 (CYP19A1). Our results uncovered the augmented T\(_{H1}\) response attributed to T\(_{reg}\) deficiency in association with ovarian dysfunction in POI, which could provide new insights into autoimmune pathogenesis and clues for novel therapeutic interventions for patients with POI.

2 | RESULTS

2.1 | Increased IFN-\(\gamma\) and TNF-\(\alpha\) in the blood and ovaries of patients with POI

To investigate whether dysregulated immunity occurs in POI, we first determined the serum cytokine profiles in patients with POI (\(N = 100\)) and control women (\(N = 100\)) with the respective enzyme linked immunosorbent assays (ELISAs). Interestingly, POI patients showed significantly increased levels of the type 1 proinflammatory cytokines IFN-\(\gamma\) (\(p < 0.0001\)) and TNF-\(\alpha\) (\(p = 0.0006\)) but reduced amounts of the regulatory cytokine TGF-\(\beta\)
(p < 0.0001) (Figure 1A). No differences were detected for other cytokines, such as IL-4 (T_{1/2}), IL-17A (T_{17}), and IL-10 (Figure 1A). IL-2 was undetectable in both controls and patients. To determine whether the dysregulated cytokine profile results from T lymphocytes, we analyzed intracellular cytokines in T cells from peripheral blood mononuclear cells (PBMCs) using flow cytometry. Compared to control women, patients with POI had an increased frequency of CD3^{+}IFN-γ^{+} T cells (p = 0.0462), CD3^{+}TNF-α^{+} T cells (p = 0.0196), and CD3^{+}TNF-α^{+}IFN-γ^{+} T cells (p = 0.0164) (Figure S1). No differences were observed for IL-17A^{+} and IL-10^{+} CD3^{+} T cells between the two groups (p > 0.05). The percentages of CD4^{+} and CD8^{+} T cells were comparable between POI patients and control subjects (Figure S1). Thus, patients with POI exhibited a systemically augmented Th1-like response.

Given the systemic increase in Th1-type response, we next determined the inflammatory cytokine profile in the ovarian microenvironment by measuring cytokines in follicular fluid (FF) and GCs in patients with biochemical POI (bPOI), which is defined as the early stage of POI and is characterized by decreased follicle quantity or quality (Figures 1B and 1C; bPOI, N = 31; control, N = 31). It is impractical to obtain FF or GCs from POI patients because of follicle depletion and ovarian atrophy. Strikingly, we found that women with bPOI already had significantly higher levels of TNF-α (p = 0.0425) in FF than did controls. As some control women and patients showed undetectable levels of IFN-γ in the FF, we calculated the positive rates of IFN-γ detection between the two groups and found that there was also a significantly higher frequency of detectable IFN-γ in bPOI patients than in controls (p < 0.0001). Interestingly, patients with bPOI showed reduced amounts of IL-10 compared to control women (p = 0.0031) (Figure 1B). IL-17A, IL-4, and IL-2 levels were undetectable in both patients and controls. In addition, ovarian GCs isolated from women with bPOI showed significantly increased expression of the inflammatory cytokines IFNG and TNF and decreased TGFBI expression compared with the control groups (p < 0.05). However, no significant differences were found in IL17A, IL4, and IL10 mRNA expression (Figure 1C). The data collectively indicate that patients with early bPOI and overt POI exhibited an increased Th1 proinflammatory response in both the periphery and ovarian microenvironments.

### 2.2 T_{reg} cell deficiency in patients with POI

The abnormal upregulation of Th1 cytokines encouraged us to explore whether T_{reg} cell deficiency exists in patients with POI, as T_{reg} cells are a key regulator to control the immune response. We first examined the number and phenotype of CD4^{+}CD25^{hi}Foxp3^{+} T_{reg} cells in PBMCs of patients with POI. We found that the frequency and absolute number of T_{reg} cells in blood were significantly decreased in women with POI compared with control subjects (Figure 2A, POI, N = 37; control, N = 45, p = 0.0089; p = 0.0371). To understand the mechanisms underlying the decrease in T_{reg} cells, we measured the proliferative rate of T_{reg} cells ex vivo with Ki-67 staining and observed that the fraction of Ki-67^{+} T_{reg} cells was decreased in patients with POI (Figure 2B, POI, N = 24; control, N = 45, p = 0.0176). In addition, patients with POI had a significantly higher proportion of apoptosis in T_{reg} cells than control women (Figure 2C, POI, N = 13; control, N = 14, p = 0.0345). The data indicate that the decrease in T_{reg} cells in patients with POI is at least partially attributed to their reduced proliferation and increased apoptosis.

We then investigated the suppressive function of T_{reg} cells in POI patients. Given the very limited amounts of blood samples obtained from patients, it was technically impossible to study T_{reg} cell suppression with standard in vitro suppressor T cell assays. Instead, we analyzed the expression of Foxp3, CTLA-4, and GITR, which are indicators of T_{reg} cell function. We found that T_{reg} cells in women with POI exhibited significantly lower levels of Foxp3 expression, as determined by mean fluorescence intensity (Figure 2D, POI, N = 37; control, N = 45, p = 0.0318), and reduced CTLA-4 positive cells (Figure 2E, POI, N = 22; control, N = 45, p < 0.0001) compared to control women. However, the GITR expression was comparable between the two groups (Figure 2E, POI, N = 25; control, N = 42, p = 0.6660). Thus, patients with POI show a decreased number and impaired suppressive function of T_{reg} cells, suggesting that a defect in T_{reg} cells might account for the increased levels of proinflammatory cytokines IFN-γ and TNF-α in patients with POI.

### HIGHLIGHTS

- Deficient T_{reg} cells fail to restrain augmented Th1 response in POI patients.
- The increased ratio of Th1: T_{reg} cells correlates with severity of POI.
- T_{reg} cells prevent and reverse Th1-mediated ovarian insufficiency in mice.
- Th1 cytokines impair GCs growth and steroidogenesis by modulating CTGF and CYP19A1.
An increased ratio of T<sub>H1</sub> cytokines to T<sub>reg</sub> cells correlates with the severity of ovarian insufficiency in patients

To confirm that the dysregulated ratio of T<sub>H1</sub>:T<sub>reg</sub> cells is responsible for the severity of ovarian insufficiency, we conducted correlation analyses between inflammatory indicators and ovarian reserve markers in patients with POI (Table 1, Figure S2 and Table S1). As ovarian insufficiency progresses, the E2 and testosterone (T) secreted by the ovary gradually decrease, and thus, the pituitary gonadotropin FSH consecutively increases through negative feedback. We found that the amounts of the proinflammatory cytokines IFN-γ and TNF-α in the sera had strong positive correlations with FSH (IFN-γ: FSH, R = 0.36, p < 0.001; TNF-α: FSH, R = 0.43, p = 0.002), but negative correlations with E2 (IFN-γ: E2, R = -0.29, p < 0.001; TNF-α: E2, R = -0.47, p = 0.001). Intriguingly, the level of serum TGF-β1 negatively correlated with FSH and positively correlated with E2 (TGF-β1: FSH, R = -0.37, p < 0.001; TGF-β2: E2, R = 0.29, p < 0.001). Consistently, TGFBI mRNA expression in GCs was positively associated with E2 (R = 0.33, p = 0.04). Significantly, T<sub>reg</sub> cells exhibited a strong negative correlation with FSH and were positive for E2 and T (T<sub>reg</sub>: FSH, R = -0.25, p = 0.047; T<sub>reg</sub>: E2, R = 0.27, p = 0.04; T<sub>reg</sub>: T, R = 0.27, p = 0.04), suggesting their role in maintaining ovarian reserve and function. Similar correlations were also seen in the ratios of T<sub>reg</sub>:CD3<sup>+</sup>TNF-α<sup>+</sup> cells or T<sub>reg</sub>:CD3<sup>+</sup>TNF-α<sup>+</sup>IFN-γ<sup>+</sup> cells and the levels of FSH, E2 and T (p < 0.05) (Table 1). Moreover, the negative correlation of FSH with Foxp3 intensity and CTLA-4 expression further reinforced these associations (Foxp3: FSH, R = -0.26, p = 0.04; CTLA-4: FSH, R = -0.38, p = 0.01). Overall, the correlation analyses suggest a potential causative role of T<sub>H1</sub>:T<sub>reg</sub> imbalance in the pathogenesis of POI.

T<sub>reg</sub> cells ameliorate experimental POI by suppressing the T<sub>H1</sub> response

We next determined the role of T<sub>H1</sub> cell-mediated inflammation in the pathogenesis of ovarian insufficiency and the regulatory function of T<sub>reg</sub> cells in suppressing T<sub>H1</sub> cells in experimental POI models in mice. First, we utilized...
FIGURE 2 Decreased and functionally impaired CD4+CD25hiFoxp3+ Treg subsets in patients with POI. (A) Representative flow cytometry plots and the statistical analysis of frequency and absolute number of CD4+CD25hiFoxp3+ Treg cells gated on CD3+CD4+ T cells from PBMC in control women (n = 45) and patients with POI (n = 37). (B) Representative flow cytometry plots and the statistical analysis of frequency of Ki-67+ cells gated on CD4+CD25hiFoxp3+ Treg cells in control women (n = 45) and patients with POI (n = 24). (C) Representative flow cytometry plots and the statistical analysis of frequency of Annexin V−/7-AAD− cells gated on CD4+CD25hiCD127dim/- Treg cells in control women (n = 14) and patients with POI (n = 13). (D) Representative flow cytometry plots and the statistical analysis of MFI of Foxp3 from CD4+CD25hiFoxp3+ Treg cells in control women (n = 45) and patients with POI (n = 37). (E) The statistical analysis of frequency of CTLA-4+ and GITR+ cells gated on CD4+CD25hiFoxp3+ Treg cells in control women (n = 45) and patients with POI (n = 25). Data were shown as scatter plots (mean ± SEM) and analyzed by unpaired two-tailed Student’s t-test.

a classic model of colitis induced by adoptive transfer of normal CD4+CD25−45RBhi T cells into Rag1−/− recipient mice,21 which also induced ovarian insufficiency mimicking human POI. The function of Treg cells was determined by cotransfer of CD4+CD25+GFP+ cells isolated directly from Foxp3-GFP transgenic mice (experimental scheme in Figure 3A). After 5 weeks, Rag1−/− mice transferred with CD4+CD25−CD45RBhi T cells exhibited the ovarian insufficiency phenotype, with smaller ovarian size and decreased number of follicles in different stages (POI group, Figures 3B and 3C). The levels of estradiol and progesterone were also markedly decreased (Figure 3D). As excessive apoptosis of GCs is recognized as one of the important mechanisms in premature follicle atresia and depletion,22,23 we analyzed GC apoptosis in ovaries with immunohistochemical staining of cleaved PARP. We found that the proportion of cleaved PARP-positive cells per follicle was much higher in the POI group, and the apoptotic signals were specifically distributed in the GCs of growing antral follicles, indicating increased apoptosis of GCs in growing follicles associated with ovarian dysfunction and POI (Figure 3E). Importantly, increased gene expression of proinflammatory cytokines (Ifng, Tnf, and Il1b) and chemokines (Ccr1, Ccr2, and Cxcl10), and decreased expression of genes related to ovarian function (Cyp19a1, Cyp11a1, and Fshr) were observed in the ovaries.
TABLE 1  Correlation between immune indicators in peripheral with biomarkers of ovarian reserve

| Variables       | FSH       | E2       | T        |
|-----------------|-----------|----------|----------|
|                 | R         | P        | R        | P        | R        | P        |
| serum IFN-γ     | 0.36      | <0.001   | −0.29    | <0.001   | −0.11    | 0.15     |
| serum TGF-β1    | −0.37     | <0.001   | 0.29     | <0.001   | 0.12     | 0.11     |
| serum IL-17A    | −0.003    | 0.97     | 0.06     | 0.39     | −0.01    | 0.91     |
| serum IFN-γ/TGF-β1 | 0.49       | <0.001   | −0.37    | <0.001   | −0.11    | 0.14     |
| serum IL17-A/TGF-β1 | 0.33       | <0.001   | −0.20    | 0.01     | −0.03    | 0.66     |
| serum TNF-α     | 0.43      | 0.002    | −0.47    | 0.001    | 0.01     | 0.96     |
| serum IL-10     | −0.08     | 0.52     | −0.02    | 0.87     | −0.04    | 0.77     |
| %Treg           | −0.25     | 0.047    | 0.27     | 0.04     | 0.27     | 0.04     |
| %Treg/%CD3+TNF-α | −0.29     | 0.02     | 0.29     | 0.03     | 0.31     | 0.02     |
| %Treg/CD3+IFN-γ | −0.17     | 0.20     | 0.20     | 0.13     | 0.23     | 0.08     |
| %Treg/CD3+TNF-α+IFN-γ | −0.33 | 0.01     | 0.31     | 0.02     | 0.22     | 0.11     |
| Foxp3 MFI       | −0.26     | 0.04     | 0.04     | 0.73     | 0.06     | 0.63     |
| %CTLA-4+Treg    | −0.38     | 0.01     | 0.05     | 0.74     | 0.08     | 0.60     |
| %Ki-67+Treg     | −0.16     | 0.22     | 0.09     | 0.52     | 0.21     | 0.13     |

Data were analyzed by Spearman’s correlation. Abbreviations: E2, Estradiol; FSH, follicle stimulating hormone; T, testosterone.

of mice receiving CD4+CD25−45RBhi T cells (Figure 3F). Flow cytometry analysis of single cells in ovaries revealed massive infiltration of lymphocytes predominated by CD4+IFN-γ+TNF-α+ T cells, whereas IL-17A+ T cells and Foxp3+ Treg cells were virtually absent, suggesting a key role of T cells in the disease (Figure 3G). In contrast, mice receiving cotransferred Treg cells (POI+Treg) exhibited little or no infiltration of lymphocytes in ovaries, which was similar to the unmanipulated control mice (Figure 3G). Cotransfer of Treg cells effectively prevented ovarian weight loss, improved ovarian function, reduced the amounts of proinflammatory cytokines in the ovary and decreased GC apoptosis (Figures 3B-3E). Consistently, the mRNA expression of the genes that reflected ovarian function, including Cyp19a1, Cyp11a1, and Fshr, was also augmented, which was accompanied by a reduction in the mRNA expression of cytokines and chemokines (Figure 3F). The data demonstrated a dramatic amelioration of ovarian insufficiency following Treg cell cotransfer. The number of IFN-γ- and TNF-α-producing CD4+ T cells was also reduced in the ovary (Figure 3G), spleen and draining lymph nodes (Figures 3H and 3I). The data collectively indicate a key role of Treg cells in suppressing the pathogenic function of TH1 inflammation in the ovary.

2.5 Treg cell depletion exacerbates ovarian insufficiency by increasing TH1 cells in the ovary

To further validate the regulatory function of Treg cells in experimental POI, we depleted endogenous Treg cells with anti-CD25 antibody (PC61) in another model of POI induced by immunization with Zp3 peptide emulsified in CFA24 (experimental scheme in Figure 4A). Before ZP3/CFA immunization, more than 50% of CD4+Foxp3+ Treg cells were effectively depleted in peripheral blood by anti-CD25 antibody administration (Figure 4B). After 3 weeks, we found that the mice injected with anti-CD25 antibody had ovaries that were more atrophic, with smaller ovarian size, decreased ovarian weight, premature follicle depletion and ovarian fibrosis (Figures 4C and 4D). Decreased expression of genes related to ovarian steroidogenesis and function (Amh and Cyp11a1) was also detected in ovaries of the anti-CD25 antibody group (Figure 4E). Flow cytometry analysis in ovaries revealed substantially increased infiltration of IFN-γ- and TNF-α-producing T cells and a marked decrease of CD4+Foxp3+ Treg cells in the anti-CD25 antibody group (Figure 4F). The increased TH1 inflammation after Treg cell depletion in ovaries was further confirmed by the significantly increased mRNA expression of the proinflammatory cytokines Ifng and Tnf (Figure 4E). The data collectively indicate that Treg cells play a key role in preventing and suppressing experimental POI by inhibiting TH1 cells.

2.6 IFN-γ and TNF-α impair cell growth and steroidogenesis of human granulosa cells in culture

Having observed the positive correlation between TH1 cytokines and the severity of POI and validated the key pathogenic role of these cytokines in experimental
**FIGURE 3** T<sub>reg</sub> cells ameliorate experimental POI by suppressing Th1 response. (A) The experimental scheme of the adoptive transfer model. (B) The representative ovary gross photos and statistics of ovary/body weight ratio in control (n = 6), POI (n = 8), and POI+T<sub>reg</sub> (n = 10) group. (C) Representative histology images of ovary sections (scale bars, 600 μm) and quantification of ovarian follicles in three groups. (D) Serum estradiol and progesterone level detected by radioimmunology in three groups. (E) Representative immunohistochemical images and statistics of cleaved-PARP in ovarian granulosa cells (scale bars, 20 μm). (F) Gene expression of inflammatory cytokines and chemokines, and genes related to ovarian function by qRT-PCR in ovaries. (G) Representative flow cytometry plots of infiltrated CD4<sup>+</sup> T cells in ovary in three groups and statistics of CD4<sup>+</sup> T cells and different subsets in POI and POI+T<sub>reg</sub> groups. The ovarian cells from two mice were pooled together as one sample for FACS. (H) Representative flow cytometry plots and statistics of CD4<sup>+</sup> T cells and different subsets in spleens in POI and POI+T<sub>reg</sub> group. (I) Representative flow cytometry plots and statistics of CD4<sup>+</sup> T cells and different subsets in ovary-draining lymph nodes in POI and POI+T<sub>reg</sub> group. The experiments were repeated for three times, and data from one representative experiment were shown. All data were shown as scatter plots (mean ± SEM) and analyzed by one-way ANOVA test (B-F) and unpaired two-tailed Student’s t-test (G-I).
FIGURE 4 Treg depletion aggravated premature ovarian insufficiency in mice. (A) The experimental scheme of Treg depletion in experimental POI model. (B) Representative flow cytometry plots and statistics of percentage of Treg cells in PBMC of the isotype antibody (ISO Ab) and anti-CD25 antibody (aCD25 Ab) treated groups on day 0. (C) Representative photo of gross ovary and statistics of body weight, ovary weight and ovary/body weight ratio in ISO Ab and aCD25 Ab group. (D) Representative histology images of ovary sections (scale bars, 600 μm) in ISO Ab and aCD25 Ab group. (E) Gene expression of inflammatory cytokines and factors related to ovarian function by qRT-PCR in the ovaries of ISO Ab and aCD25 Ab group. (F) Representative flow cytometry plots and statistics of percentage (fold change relative to ISO Ab group) and absolute number (fold change relative to ISO Ab group) of infiltrated immune cells in ovary in ISO Ab and aCD25 Ab group. The ovarian cells from two mice were pooled together as one sample for FACS. The experiments were repeated for three times, and data from one representative experiment were shown. All data were expressed as the mean ± SEM and analyzed by the unpaired two-tailed Student’s t-test.

POI in vivo, we next investigated the functional impact of TH1 cytokines on human ovarian GCs in vitro. We cultured human KGN cells in the presence of rhIFN-γ (50.0 ng/ml) and rhTNF-α (50.0 ng/ml) either alone or in combination for 48 h and measured their apoptosis and proliferation. We found that IFN-γ and TNF-α induced profound increase in cell apoptosis and a decrease in the proliferation of human KGN cells (Figures 5A and 5B). Consistently, both cytokines substantially increased cleaved PARP but decreased PCNA expression, indicating that IFN-γ and TNF-α could impair cell growth by promoting apoptosis and decreasing proliferation (Figure 5C). It is well known that the synthesis and secretion of estrogen is the principal endocrine function of GCs and is mediated by the critical rate-limiting enzyme CYP19A1 aromatase preferentially expressed in GCs. We found that estradiol production by human KGN cells was significantly impaired upon IFN-γ and TNF-α treatment (Figure 5D). Meanwhile, IFN-γ and TNF-α treatment significantly decreased the mRNA and protein expression of CYP19A1 (Figure 5E). Importantly, synergistic reduction in GC growth, and steroidogenesis was observed with the combination of IFN-γ and TNF-α compared to either cytokine alone (Figures 5A-5E). Taken together, these data indicate that IFN-γ and TNF-α directly result in granulosa cell dysfunction and thus contribute to follicle atresia and ovarian insufficiency.

2.7 A role of CTGF in TH1 cytokine-induced granulosa cell apoptosis

We next investigated the molecular mechanisms downstream of the effects of IFN-γ and TNF-α on GCs.
A number of functional signature genes of GCs including CTGF, inhibin beta A (INHBA), Wilms’ tumor gene 1 (WT1), the forkhead transcription factor (FOXO1), and GATA binding protein 6 (GATA6), were first examined by RT-qPCR. We found significantly decreased CTGF and INHBA but increased WT1 mRNA expression in cultures after IFN-γ and TNF-α exposure (Figure 6A). Given the contradictory effect of IFN-γ plus TNF-α treatment compared with IFN-γ or TNF-α alone on INHBA expression, we then focused on the protein expression of CTGF and WT1 after cytokine exposure. Interestingly, only CTGF exhibited consistent downregulation at both the mRNA and protein levels (Figure 6B). To further determine whether the effects of IFN-γ and TNF-α on GCs were mediated by CTGF, we downregulated endogenous CTGF expression by employing shRNA transfection in KGN cells (Figure 6C). We found that CTGF reduction had no effect on estradiol synthesis or CYP19A1 expression in KGN cells in response to IFN-γ and TNF-α treatment (Figure 6D). However, downregulation of CTGF significantly enhanced the apoptosis and suppressed the proliferation of KGN cells, which was further evidenced by increased cleaved PARP expression and decreased PCNA expression (Figures 6E-6G). Conversely, the addition of exogenous rhCTGF to KGN cells effectively rescued the cell apoptosis induced by both cytokines (Figure 6H). These data indicate that CTGF deficiency is critical for TH1 cytokine-induced growth impairment in granulosa cells.

2.8 IFN-γ and TNF-α downregulate CTGF through JAK-STAT1 and NF-κB activation

We next explored how IFN-γ and TNF-α regulated CTGF expression. The janus kinase (JAK)/signal transducer and activator of transcription-1 (STAT1) and nuclear factor kappa-B (NF-κB) signaling was activated by IFN-γ and TNF-α, as evidenced by increased phosphorylation of STAT1, IKBα, and p65 in human KGN cells (Figure 6I).
The role of CTGF in IFN-γ and TNF-α-induced granulosa cell apoptosis and steroidogenesis. (A and B) The human KGN cells were treated in the absence or presence of rhIFN-γ (50.0 ng/ml), rhTNF-α (50.0 ng/ml) or a combination for 48 hours. (A) Expression of different markers related to granulosa cell function analyzed by qRT-PCR. (B) Expression of CTGF and WT1 protein detected by western blot. (C-G) The human KGN cells were transfected with 50 nM CTGF siRNA (Si-CTGF) and 50 nM control siRNA (Si-NC) for 48 h to silence endogenous CTGF expression. (C) The efficiency of sh-CTGF was confirmed by qRT-PCR (left) and western blot (right). (D) Estradiol production was measured by Chemiluminescence (left) and CYP19A1 protein level detected by western blot (right). (E) Statistics of the percentage of Annexin V/7-AAD double positive cells. (F) Statistics of the percentage of Edu positive cells. (G) Cleaved-PARP and PCNA protein level detected by western blot. (H) The human KGN cells were cultured with rhCTGF (20.0 ng/ml) in the presence of rhIFN-γ (50.0 ng/ml), rhTNF-α (50.0 ng/ml), or a combination for 48 h. Statistics of frequency of Annexin V/7-AAD double positive cells. (I-J) The human KGN cells were treated with or without 10 μM inhibitor of JAK/STAT1 (AG-490) and 5 μM inhibitor of NF-κB (Bay11-7082) for 1 h prior to cytokines stimulation. (I) The expression of CTGF, STAT1 and p-STAT1, p-P65, p-IκBα was detected by western blot (left). CTGF protein quantification was analyzed by being normalized to α-tubulin (right). (J) Estradiol production was measured by Chemiluminescence (left) and normalized to the control group; CYP19A1 protein level was examined using western blot (right). (K) The human KGN cells were treated with 1 μg/ml neutralizing antibody for IFN-γ and TNF-α for 1 h followed by treatment with cytokines. The expression of CTGF, STAT1 and p-STAT1, p-P65, p-IκBα was detected by western blot. Data were presented relative to the control group. The results were expressed as mean ± SEM from at least three independent experiments. Data were analyzed by the one-way ANOVA test (A and H-J) or unpaired two-tailed Student’s t-test (C-F).

The addition of inhibitors of JAK or IκBα phosphorylation attenuated IFN-γ- and TNF-α-induced inhibitory effects on CTGF expression in KGN cells (Figure 6I). CTGF expression was also reversed when using neutralizing antibodies against IFN-γ and TNF-α (Figure 6K). However, the suppression of E2 synthesis by IFN-γ and TNF-α could not be reversed by either JAK/STAT1 or NF-κB inhibitors (Figure 6J). Similar results were obtained in murine primary GCs in cultures (Figure 7). These data indicate that IFN-γ and TNF-α downregulate CTGF in granulosa cells via JAK-STAT1 and NF-κB activation.

3 | DISCUSSION

Here for the first time we have comprehensively characterized the phenotype and function of immune responses in human ovarian insufficiency. Our data provide
compelling evidence that patients with POI have decreased and functionally impaired CD4⁺CD25⁺Foxp3⁺ Treg cells and increased TH1-dominant inflammation in both the periphery and ovarian microenvironments. This Treg:TH1 disturbance and altered inflammatory cytokine profile were strongly correlated with progression of human ovarian insufficiency, and the potentially causative effects were validated in experimental POI in mice. The increased IFN-γ and TNF-α impair steroidogenesis by targeting CYP19A1 and promote apoptosis of GCs in part by down-regulating CTGF via JAK-STAT1 and NF-κB activation, hence contributing to follicle atresia, ovarian dysfunction, and premature insufficiency (proposed model, Figure 8).

The immune system is critical for optimal ovarian homeostasis and reproductive function. However, the pathogenic functions of the immune cells in POI have not been clearly elucidated. Here, we revealed that the TH1-like cytokines, particularly IFN-γ and TNF-α, may contribute to the pathogenesis of POI. Evidence supporting this conclusion included selectively systemic and ovarian increases in the proinflammatory cytokines TNF-α and IFN-γ and related TH1 cells. Intriguingly, other T cell subsets such as TH2 and TH17 cells and their signature cytokines were not found to change in POI patients. This suggests that POI is likely a TH1-mediated autoimmune disorder.

In exploring the underlying mechanisms for the preferential increase in TH1-like proinflammatory cytokines in POI, we discovered that deficiency in the number and function of Treg cells might play a key role. Several findings supported this conclusion. Although a decrease in CD4⁺CD45RA⁻Foxp3hi effector Treg cells was reported in POI patients, the detailed phenotype and functional relevance of Treg cells in maintaining ovarian function were still unclear. We have revealed that the decrease in Treg cells was attributable to their reduced proliferation and increased apoptosis in POI patients. Given the lack of suitable and validated markers to distinguish naturally occurring Treg cells and induced Treg cells in complex contexts in humans, no further subtyping was explored here. Importantly, we uncovered that Treg cells in POI patients displayed reduced Foxp3 and CTLA-4 expression, which accounts for the compromised suppressive ability of Treg cells. In addition, the decreased
The proposed working model of POI. The Treg cells deficiency with decreased number and impaired suppression function could mediate augmented T\(_{H1}\) responses in premature ovarian insufficiency (POI). The increased T\(_{H1}\) proinflammatory cytokines IFN-\(\gamma\) and TNF-\(\alpha\) impair steroidogenesis by targeting CYP19A1 and promote apoptosis of granulosacellspartiallyby
down-regulationofCTGFviaJAK-STAT1andNF-\(\kappa\)Bactivation,
hencecontribute to follicle atresia, ovarian dysfunction and prematureinsufficiency

Inhibitory cytokines IL-10 and TGF-\(\beta\) may also contribute to the increased T\(_{H1}\) like inflammatory cytokines in POI patients, although the cellular sources of these regulatory cytokines remain unknown. More importantly, the strong correlations between IFN-\(\gamma\), TNF-\(\alpha\), or Treg cells and markers of ovarian function further support that the regulation of T\(_{H1}\) like inflammation by Treg cells contributes to immune homeostasis in the ovary and the maintenance of ovarian function.

Determining the effect of the Treg cell deficiency-mediated increase in T\(_{H1}\) inflammation on ovarian insufficiency is of great importance to clarify the pathogenesis of POI. By using two different animal models of experimental POI, we confirmed the causative role of IFN-\(\gamma\) and TNF-\(\alpha\) cytokines in POI mice and elucidated the key function of Treg cells in controlling T\(_{H1}\) like inflammatory responses. In Rag1\(^{-/-}\)mice that were adoptively transferred with CD4\(^+\)CD25\(^-\)CD45RB\(^{hi}\) T cells, a massive infiltration of immune cells, predominated by IFN-\(\gamma\), and TNF-\(\alpha\)-producing CD4\(^+\) T cells, was observed in inflamed ovaries. These mice exhibited the phenotype of ovarian insufficiency. Of note, the apoptosis of GCs was preferentially distributed in the growing follicles, consistent with previous reports on oophoritis, in which

The immune response was privileged mainly in antral and growing follicles. These data indicate that augmented T\(_{H1}\) response with IFN-\(\gamma\) and TNF-\(\alpha\) is the major force that induces accelerated follicle atresia. Support for this claim also came from the fact that cotransfer of Treg cells significantly restrained the T\(_{H1}\) effector cell response in the ovary and consequently alleviated ovarian damage and greatly restored ovarian function. In contrast, Treg cell depletion in ZP3-induced POI mice resulted in exacerbated activation and expansion of CD4\(^+\) T cells and the production of T\(_{H1}\) cytokines in the ovary and consequently aggravated ovarian atrophy. These findings provide compelling evidence that T\(_{H1}\)-like inflammatory cytokines play a deleterious role in the ovarian microenvironment in POI, which is controlled primarily by the number and intact function of Treg cells.

The follicular microenvironment is critical for folliculogenesis and the acquisition of oocyte competence. A cascade of intraovarian/perifollicular cytokines and chemokines could mediate communication among lympho-hemopoietic cells, somatic cells and oocytes by autocrine or paracrine action. Having demonstrated increased IFN-\(\gamma\) and TNF-\(\alpha\) in POI patients and experimental POI mouse models, we further clarified that IFN-\(\gamma\) and TNF-\(\alpha\) directly affected the GC growth and steroidogenesis. Exposure to IFN-\(\gamma\) or TNF-\(\alpha\) profoundly induced apoptosis and suppressed proliferation and thus impaired GC growth. In addition, both cytokines downregulated the key enzyme CYP19A1 aromatase and consequently decreased E2 levels. Importantly, estradiol contributes to GC proliferation and follicle differentiation as an intraovarian regulator in folliculogenesis. Therefore, dysregulation of steroidogenesis in GCs might aggravate the apoptosis induced by IFN-\(\gamma\) and TNF-\(\alpha\) exposure, and vice versa. Taken together, these results indicated that T\(_{H1}\) inflammatory cytokines induce GC apoptosis and dysfunction and contribute to follicle atresia.

CTGF, highly expressed in the granulosa cells of growing follicles as an autocrine/paracrine factor, is a critical regulator of granulosa cell differentiation, follicle growth, tissue remodeling, and ovulation involved in folliculogenesis. Of the crucial genes related to GC function, CTGF was found to be one of the core targets given its significant and consistent changes at both the transcriptional and translational levels after IFN-\(\gamma\) and TNF-\(\alpha\) exposure. We have revealed that the proapoptotic effect of IFN-\(\gamma\) and TNF-\(\alpha\) on GCs is mediated by CTGF downregulation, evidenced by increased apoptosis and decreased proliferation after CTGF silencing and by reduced apoptosis after rhCTGF treatment. This was consistent with the findings in granulosa cell-specific Ctgf deficiency in mice, which showed increased GC
apoptosis, disrupted follicular development and reduced fertility.\textsuperscript{34} It has been reported that IFN-\(\gamma\) and TNF-\(\alpha\) could reduce CTGF promoter activity and decrease its expression via the STAT1 and NF-\(\kappa\)B pathways in dermal fibroblasts, pancreatic stellate cells, and lung endothelial cells.\textsuperscript{35–37} However, the modulation of CTGF by both cytokines in GCs is unclear. We found that after exposure to IFN-\(\gamma\) and TNF-\(\alpha\), JAK-STAT1 and NF-\(\kappa\)B signaling were activated with increased expression of p-STAT1, p-IKB\(\alpha\), and p-P65 in GCs. With JAK inhibitors, IKB\(\alpha\) phosphorylation inhibitors or IFN-\(\gamma\) /TNF-\(\alpha\) neutralization, the effect of both cytokines on CTGF downregulation was attenuated, indicating that the JAK-STAT1 and NF-\(\kappa\)B pathways participate in the regulation of IFN-\(\gamma\) and TNF-\(\alpha\) on CTGF in human GCs. The data provide the mechanism by which IFN-\(\gamma\) and TNF-\(\alpha\) promote granulosa cell apoptosis, at least partially by downregulating CTGF through the JAK-STAT1 and NF-\(\kappa\)B pathways, respectively.

Of note, estrogen has been extensively studied for its immunomodulatory role in different immune responses.\textsuperscript{38,39} Generally, low E\textsubscript{2} concentrations promote T\textsubscript{H}1-type responses and increase IFN-\(\gamma\) production, whereas high E\textsubscript{2} levels augment T\textsubscript{H}2-type responses.\textsuperscript{40–42} In addition, exogenous E\textsubscript{2} could drive T\textsubscript{reg} expansion and enhance the conversion of naïve CD4\textsuperscript{+}CD25\textsuperscript{−} T cells to CD4\textsuperscript{+}CD25\textsuperscript{+} T\textsubscript{reg} cells with increased Foxp3 expression.\textsuperscript{43–45} We have revealed that the T\textsubscript{reg} cell deficiency-mediated increase in T\textsubscript{H}1 inflammation impaired steroidogenesis in GCs, which might account for the low estrogen in patients with POI. Meanwhile, the low estrogen status would also restrain T\textsubscript{reg} cell number and function so that T\textsubscript{reg} cells could not efficiently suppress T\textsubscript{H}1 inflammation. Consistently, an increase in proinflammatory cytokines, such as IL-1\(\beta\), IFN-\(\gamma\), TNF-\(\alpha\), and MCP-1 has also been reported in the post-menopausal women.\textsuperscript{46} Therefore, the long-term estrogen deficiency in POI patients might facilitate the skewing of immune tolerance toward T\textsubscript{H}1 immunity and in turn underlie the exacerbation of ovarian insufficiency. The mutual interaction between hormone dysregulation and immune disturbance result in an extreme negative feedback loop, ultimately leading to the progression of ovarian insufficiency. It is postulated that low estrogen status might also confer greater susceptibility and even participate in the onset of concomitant autoimmune diseases with POI.

Currently, there remains no effective strategy to ameliorate ovarian function and fertility for patients with POI. Typically, these women ultimately pursue egg donation or adoption. The POI patients with autoimmune disturbance usually have residual follicles and might benefit from early immune intervention.\textsuperscript{47,48} Our data quantify-ing the decreased number and functional impairment of T\textsubscript{reg} cells in patients with POI and the effectiveness of T\textsubscript{reg} adoptive transfer in murine POI suggest a potential for T\textsubscript{reg}–mediated treatment in the clinic. Hopefully, with efforts in T\textsubscript{reg} cell engineering to enhance their specificity, stability, and functional activity, T\textsubscript{reg} cell therapy will become a practical method for POI treatment.

In summary, we characterized the immune signature and cytokine milieu in women with POI and demonstrated that POI may result from a breakdown of immunological self-tolerance evidenced by T\textsubscript{reg} cell deficiency and consequently unrestrained immune destruction by an exacerbated T\textsubscript{H}1 response. These results provide new insights into the pathogenesis of POI and pave the way for novel therapeutic interventions for patients.

4 | METHODS AND MATERIALS

4.1 | Human subjects

All participants were recruited from the Center for Reproductive Medicine, Shandong University from October 2016 to November 2019. In total, patients with POI and biochemical POI (bPOI) and control women with normal ovarian reserve were selectively recruited. The inclusion criteria for POI included secondary amenorrhea for at least 4 months, serum basal FSH > 25 IU/L (on two occasions > 1 month apart) before age 40 according to the ESHRE and Chinese guideline.\textsuperscript{1,2} BPOI, by some also called premature ovarian aging, was defined as regular or irregular menstes and elevated basal serum FSH (10 IU/L < FSH ≤ 25 IU/L, on two occasions > 4 weeks apart) and antral follicle count (AFC) < 5 before age of 35 years old as previously reported.\textsuperscript{49,50} Women with regular menstrual cycles and normal FSH level (<10 IU/L) sought for infertility treatment due to tubal obstruction or male factors were recruited as controls. Women with chromosomal abnormality, known gene mutations, history of ovarian surgery, radio-or chemo-therapy, history of recurrent spontaneous abortion, endometriosis or autoimmune disease, and infection in the previous three months, were excluded. The baseline characteristics are described in Tables S2 and S3. There are inevitable limitations which might confound the measurement of FF and granulosa cells, due to different controlled ovarian hyperstimulation protocols administered based on different phenotypic characteristics of patients undergoing in vitro fertilization/ intracytoplasmic sperm injection and embryo transfer (IVF/ICSI-ET). The human study was approved by the Institutional Review Board of Center for Reproductive Medicine, Shandong University. All participants had signed the written informed consent forms.
Female C57BL/6, B6AF1 and Rag1−/− mice (8- to 10-week-old) were obtained from The Jackson Laboratory. Foxp3GFP-Cre mice (on a C57BL/6 background) were bred in our National Institutes of Health (NIH) facility (Bethesda, MD, USA). These mice were used for experimental POI models and housed in NIH facility. Rag2−/− mice purchased from Shanghai Model Organisms (Shanghai, China) and Foxp3YFP-Cre mice provided by Dr. B. Li (Shanghai Jiaotong University School of Medicine, Shanghai, China) were housed in animal facility of Experimental Animal Center of Shandong University (EAC-SDU, Jinan, China), and used for some replication experiments. The immature female C57BL/6 mice (3-week-old) were purchased from EAC-SDU for GC isolation. All mice were housed in specific pathogen-free conditions. All animal studies were performed according to NIH and SDU guidelines for the use and care of live animals and were approved by the Animal Care and Use Committees of the National Institute of Dental and Craniofacial Research (NIDCR), NIH and School of Medicine, Shandong University.

### 4.3 Hormone measurement and pelvic ultrasonography

Peripheral blood was sampled on day 2–4 of menstrual cycle or randomly (for women not menstruating frequently) in all patients and controls. Levels of basal FSH, luteinizing hormone, estradiol (E₂), and total testosterone (T) were measured by chemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany). The intra-assay and inter-assay coefficients of variation were 10%. Transvaginal ultrasonography was routinely conducted and AFC was defined as the number of follicles 2–10 mm in early follicular phase.

### 4.4 Cell isolation

Human peripheral blood was collected to isolate PBMC using Ficoll-Hypaque (MP Biomedicals, Santa Ana CA, USA) gradient centrifugation. Human GCs and FF were obtained from patients with bPOI and controls undergoing IVF/ICSI-ET.

Murine lymphoid tissues (spleen and draining lymph nodes) were thoroughly minced and consecutively passed through the 70-μm mesh strainer (BD Biosciences, San Jose, CA, USA) to obtain single-cell suspensions. To prepare single cell suspension from ovary, ovaries from two mice were isolated, mixed and cut into small pieces, followed by enzymatic digestion for 20 minutes at 37°C in

plain RPMI buffer (HyClone, Thermo Fisher Scientific, Waltham, MA, USA) with Collagenase IV (4 mg/ml; Gibco, Thermo Fisher Scientific) and DNase (0.01 mg/ml; Sigma, Louis, MO, USA), and then mashed through 70-μm cell strainers.

Immature female C57BL/6 mice (3-week-old) were injected with 200 IU pregnant mare serum gonadotropin (PMSG, SANSHEng, Ningbo, Zhejiang, China) by intraperitoneal to stimulate follicle growth for 44 h. The ovaries were removed and primary GCs were isolated and harvested from large antral follicles by needle puncture.

### 4.5 ELISA assay for cytokines

The concentrations of different cytokines in human sera and FF were analyzed with a sandwich ELISA protocol. All the high-sensitive kits were purchased from eBioscience (Thermo Fisher Scientific). The optical intensity was read at 450 nm as the primary wave length and 620 nm as the reference wave length on an automated microplate reader (Tecan, Switzerland). The 5-parameter curve fit was used to determine the concentration of cytokines according to the manufacturer’s instruction.

### 4.6 Flow cytometry

Dead cells were excluded from analysis using Zombie Yellow or Aqua Fixable Viability Kit (BioLegend, San Diego, CA, USA). For cell-surface staining, 10^6 cells per sample were incubated with various antibodies in staining buffer (phosphate-buffered saline (PBS) and 2.5% fetal bovine serum) for 15 min at room temperature in the dark. For intranuclear staining, the cells were fixed and permeabilized in Fixation/Permeabilization buffer solution (eBioscience, Thermo Fisher Scientific) at 4°C for 1 h. For intracellular cytokine staining, cells were stimulated with Cell activation cocktail (BioLegend) at 37°C for 4 h, and then fixed and permeabilized with the Fixation/Permeabilization buffer solution (BD Biosciences) at 4°C for 20 min according to the manufacturer’s instructions. Stained cells were acquired on an LSR Fortessa cell analyzer (BD Biosciences), and data were analyzed with FlowJo software (V 10.6.1, BD Biosciences, Ashland, OR, USA). The antibodies used are listed in Supplemental Table S4.

### 4.7 Adoptive transfer model of oophoritis and POI

Rag1−/− recipients were injected i.p. with FACS-sorted naive CD4+CD25−CD45RBhi T cells (4 × 10^5 cells/mouse;
BD FACSAria II) in the presence (POI + T_{reg} group) or absence (POI group) of FACS-sorted CD4^+CD25^{hi}GFP^+ T_{reg} cells (2.5 × 10^5 cells/mouse; BD FACSAria II) from spleens and peripheral lymph nodes of Foxp3^{GFP-Cre} mice. For replication, Rag2^{−/−} and Foxp3^{YFP-Cre} mice were used in some experiments. The Rag1^{−/−} mice injected i.p. with PBS were included as controls. The recipient mice were weighted twice a week for 5 weeks. Serum was collected and isolated for estradiol and progesterone measurements. Ovarian tissues were harvested for histopathological and immunological analyses. Spleen and ovary draining lymph nodes were isolated for FACS analysis.

4.8 T_{reg} depletion in ZP3 induced POI model

Female B6AF1 mice received two doses of anti-CD25 antibody (PC-61.5.3, BioXCell, West Lebanon, NH, USA; 500 μg/mouse; i.p.) on day 0 and 3 for T_{reg} depletion. Age-matched control recipients were treated with isotype control antibody (HRPN, Bio X Cell, West Lebanon, NH, USA; 500 μg/mouse; i.p.). All mice were immunized s.c. with 100 IU ZP3 peptide (amino acids 330–342, NSSSSQFQIHGPR, Invitrogen, Thermo Fisher Scientific) emulsified in complete Freund’s Adjuvant (CFA, Sigma, Louis, MO, USA) on day 4 to induce autoimmune ovarian insufficiency. Mice were monitored weekly and sacrificed 3 weeks later. The ovaries were isolated for histological and functional analysis. Spleen and draining lymph nodes were used for FACS analysis.

4.9 Cell culture and cytokines treatment

As a steroidogenic human granulosa-like tumor cell line, the KGN cell line obtained from RIKEN BioResource Center, Ibaraki, Japan was used for in vitro functional study. The KGN cells were cultured in DMEM/F12 medium (Thermo Fisher Scientific) containing 10% FBS (Biological Industries, Beit Haemek, Israel) and 1% penicillin/streptomycin (Thermo Fisher Scientific). Mice primary GCs were cultured in DMEM/F12 with 5% FBS. All cells were maintained in a humidified atmosphere containing 5% CO₂ at 37°C.

Cells were treated in the absence or presence of recombinant human or murine IFN-γ (PeproTech, Rocky Hill, NJ, USA), TNF-α (PeproTech, Rocky Hill, NJ, USA), or a combination for 48 h. Then the cells were evaluated in vitro for cell proliferation and apoptosis assay. For steroid hormone measurements, cells were cultured in phenol-red free DMEM/F12 medium (Thermo Fisher Scientific) containing 10% charcoal-stripped FBS (Thermo Fisher Scientific). After 48 hours’ culture, the culture medium was supplemented with 10 nmol/ml testosterone as a substrate for estradiol generation for 24 h. The supernatant media was retained for estradiol measurement, and cells lysates were stored at −80°C until total RNA and protein extraction.

4.10 Cell proliferation and apoptosis assay

Cell proliferation was further carried out using Cell-Light EdU Apollo 567 In Vitro Imaging Kit (RiboBio, Guangzhou, China) according to the manufacturer’s instructions. The rate of EdU-positive cells was calculated with (EdU positive cells/Hoechst-stained cells) × 100%. Cell apoptosis was detected by Annexin V/7-AAD staining (BD Pharmingen, San Diego, CA, USA) and acquired on an LSR Fortessa (BD Biosciences, San Jose, CA, USA).

4.11 CTGF downregulation and human recombinant CTGF supplement

To explore the effect of CTGF on GCs function, shRNAs for CTGF (GenePharma Inc, Shanghai, China) were transfected at 50 nM using X-tremeGENE siRNA Transfection Reagent (Roche, Mannheim, Germany) to downregulate endogenous CTGF expression of KGN cells (sh-CTGF). Non-target shRNA (sh-NC) was used as control. Additionally, KGN cells were incubation with different cytokines or in combination in the presence or absence of 20.0 ng/ml recombinant CTGF (R&D, Minneapolis, MN, USA) to investigate the rescue effect of CTGF.

4.12 Pathway inhibitor or neutralizing antibody treatment

To further determine whether CTGF was directly regulated by IFN-γ and TNF-α, KGN cells were preincubated for 1 h with DMSO vehicle control, 10 μM AG-490 (a selective JAK inhibitor, Selleck, Shanghai, China) or 5 μM Bay11-7082 (an inhibitor of IKBα phosphorylation, Selleck), followed by addition of IFN-γ and TNF-α. Additionally, 1 μg/ml neutralizing antibodies of IFN-γ (R&D) and TNF-α (R&D) were added to block cytokines effects prior to cytokines stimulation.

4.13 Quantitative RT-qPCR

Total RNA was isolated using TRIzolTM reagent (Ambion, Thermo Fisher Scientific), and cDNA was generated with
Taq-Man reverse transcription reagents (Applied Biosystems) or PrimeScript RT Reagent Kits (Takara Bio). Quantitative real-time PCR was performed in triplicate using TaqMan gene expression assays (Applied Biosystems) or SYBR Premix Ex TaqTM Kit (Takara Bio) on 7500 real-time PCR System (Applied Biosystems) or Roche LightCycler 480 (Roche). The level of target gene expression was quantified after normalization to ACTB, Hprt or Gapdh expression. The primers were listed in Table S5.

4.14 Western blot analysis

Total protein was harvested with RIPA buffer (Beyotime, Jiangsu, China) containing a phenylmethylsulfonyl fluoride (PMSF, Beyotime, Jiangsu, China) and phosphatase inhibitor cocktail (Cell Signaling Technology). Protein concentrations were determined using BCA assay (Pierce, Thermo Fisher Scientific). Primary antibodies recognizing CTGF, STAT1, Phospho-STAT1, Phospho-P65 (all 1:1000, Cell Signaling Technology), CYP19A1, PCNA (all 1:1000, Proteintech), and cleaved-PARP (1:1000, Cell Signaling Technology) were incubated to examine the proteins. The α-tubulin (1:2000, Proteintech) was used as an intrinsic control. The immunoreactive bands were photographed and analyzed with ChemiDoc MP Imaging System and Image Lab Software (Bio-Rad, Hercules, CA, USA).

4.15 Histology and immunohistochemistry staining

Bouin-fixed, paraffin-embedded ovarian tissue was serially sections at 5 μm in thickness. Every fifth section was analyzed for the presence of oocytes and follicles after the H&E staining as previously described. The counting results were multiplied by five to estimate the total numbers of oocytes and follicles in each ovary. For immunohistochemistry, the sections of mice ovaries were stained with anti-cleaved-PARP (1:100, Cell Signaling Technology). The image was taken with microscope (OLYMPUS, Japan) and analyzed by ImageJ software (NIH, Bethesda, MD, USA).

4.16 Statistical analysis

All experiments were independently repeated for three times and performed in triplicate. Statistical analysis was performed using SPSS version 21 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 7 (San Diego, USA). When continuous data was normality distributed, it was shown as Mean ± standard error of the mean (SEM) and determined with the two-tailed Student’s t test or one-way ANOVA test; otherwise data were expressed as median (quartile) and compared by two-tailed Mann-Whitney U test. Categorical variables were analyzed with chi-square test. Spearman’s correlation was used to estimate the association between immune indicators and biomarkers of ovarian reserve. p < 0.05 was considered significant.

ACKNOWLEDGMENTS

Xue Jiao was supported in part by the joint PhD fellowship between Shandong University and NIH. Xue Jiao, Xiruo Zhang, Nianyu Li, Yujie Dang, Shidou Zhao, Yingying Qin, and Zi-Jiang Chen were supported by the National Key Research & Developmental Program of China (grant numbers: 2017YFC1001100 and 2018YFC1003803), the National Natural Science Foundation of China (grant numbers: 81971352 and 82071609) and Young Scholars Program of Shandong University. Dunfang Zhang, Peter Zanvit, Wenwen Jin, and Wanjun Chen were supported by the Intra-mural Research Program of National Institutes of Health (NIH), United States and National Institute of Dental and Craniofacial Research (NIDCR). We would like to thank Dr. B. Li (Shanghai Jiaotong University School of Medicine, Shanghai, China) for providing the Foxp3YFP-Cre mice.

CONFLICT OF INTEREST

The authors have declared that no conflict of interest exists.

AUTHOR CONTRIBUTIONS

Xue Jiao and Xiruo Zhang designed and performed most of the experiments, analyzed and interpreted the data, and contributed to the writing of the manuscript. Nianyu Li, Dunfang Zhang, Shidou Zhao, and Yujie Dang performed experiments, analyzed data, and contributed to the writing of the manuscript. Peter Zanvit and Wenwen Jin performed experiments and provided support and/or critical scientific input. Zi-Jiang Chen, Wanjun Chen, and Yingying Qin conceived of and directed the research, designed the experiments, and wrote the paper.

ORCID

Zi-Jiang Chen https://orcid.org/0000-0001-6637-6631
Yingying Qin https://orcid.org/0000-0002-0319-7799

REFERENCES

1. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, et al. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937.
2. Chen ZJ, Tian Q, Qiao J, et al. Chinese expert consensus on premature ovarian insufficiency. Chin J Obstet Gynecol. 2017;52(9):577–581.
3. Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. *Clin Endocrinol (Oxf)*. 2008;68(4):499–509.

4. Jiao X, Ke H, Qin Y, et al. Molecular genetics of premature ovarian insufficiency. *Trends Endocrinol Metab*. 2018;29(11):795–807.

5. Qin Y, Jiao X, Simpson JL, et al. Genetics of primary ovarian insufficiency: new developments and opportunities. *Hum Reprod Update*. 2015;21(6):787–808.

6. Silva CA, Yamakami LY, Aikawa NE, et al. Autoimmune primary ovarian insufficiency. *Autoimmun Rev*. 2014;13(4-5):427–430.

7. Kirshenbaum M, Orvieto R. Premature ovarian insufficiency (POI) and autoimmunity—an update appraisal. *J Assist Reprod Genet*. 2019;36(11):2207–2215.

8. Petrikova J, Lazurova I. Ovarian failure and polycystic ovary syndrome. *Autoimmun Rev*. 2012;11(6-7):A471–A478.

9. Jiao X, Zhang H, Ke H, et al. Premature ovarian insufficiency: phenotypic characterization within different etiologies. *J Clin Endocrinol Metab*. 2017;102(7):2281–2290.

10. Jasti S, Warren BD, McGinnis LK, et al. The autoimmune regulator prevents premature reproductive senescence in female mice. *Biol Reprod*. 2012;86(4):110.

11. Sen A, Kushnir VA, Barad DH, et al. Endocrine autoimmune diseases and female infertility. *Nat Rev Endocrinol*. 2014;10(1):37–50.

12. Gao J, Jiao X, Dang Y, et al. Identification of patients with primary ovarian insufficiency caused by autoimmunity. *Reprod Biomed Online*. 2017;35(4):475–479.

13. Warren BD, Kinsey WK, McGinnis LK, et al. Ovarian autoimmune disease: clinical concepts and animal models. *Cell Mol Immunol*. 2014;11(6):510–521.

14. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. *Nat Rev Immunol*. 2010;10(7):490–500.

15. Josephowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. *Annu Rev Immunol*. 2012;30:531–564.

16. Shevach EM. Mechanisms of foxp3+ regulatory cell-mediated suppression. *Immunity*. 2009;30(5):636–645.

17. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25−naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. *J Exp Med*. 2003;198(12):1875–1886.

18. Piccirillo CA, Shevach EM. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. *Semin Immunol*. 2004;16(2):81–88.

19. Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4+CD25high regulatory cells in human peripheral blood. *J Immunol*. 2001;167(3):1245–1253.

20. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. *J Immunol*. 2000;164(1):183–190.

21. Powrie F, Michael WL, Mauze S, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RB<sup>+</sup>CD4<sup>+</sup> T Cells. *Immunity*. 1994;1(7):553–562.

22. Sanchez F, Smitz J. Molecular control of oogenesis. *Biochim Biophys Acta*. 2012;1822(12):1896–1912.

23. Regan SLP, Knight PG, Yovich JL, et al. Granulosa cell apoptosis in the ovarian follicle—a changing view. *Front Endocrinol*. 2018;9:61.

24. Lou YH, Park KK, Agersborg S, et al. Retargeting T cell-mediated inflammation: a new perspective on autoantibody action. *J Immunol*. 2000;164(10):5251–5257.

25. Toda K, Takeda K, Okada T, et al. Targeted disruption of the aromatase P450 gene (Cyp19) in mice and their ovarian and uterine responses to 17-oestradiol. *J Endocrinol*. 2001;170(1):99–111.

26. Yang X, Gilman-Sachs A, Kwak-Kim J. Ovarian and endometrial immunity during the ovarian cycle. *J Reprod Immunol*. 2019;133:7–14.

27. Field SL, Dasgupta T, Cummings M, et al. Cytokines in ovarian folliculogenesis, oocyte maturation and luteinisation. *Mol Reprod Dev*. 2014;81(4):284–314.

28. Kobayashi M, Nakashima A, Yoshino O, et al. Decreased effector regulatory T cells and increased activated CD4(+)<sup>T</sup> cells in premature ovarian insufficiency. *Am J Reprod Immunol*. 2019;81(6):e13125.

29. Bakalov VK, Anasti JS, Calis KA, et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. *Fertil Steril*. 2005;84(4):958–965.

30. Dumesic DA, Meldrum DR, Katz-Jaffe MG, et al. Oocyte environment: follicular fluid and cumulus cells are critical for oocyte health. *Fertil Steril*. 2015;103(2):303–316.

31. Findlay JK, Brit K, Kerr JB, et al. The road to ovulation: the role of oestrogens. *Reprod Fertil Dev*. 2001;13(7-8):543–547.

32. Chang HM, Pan HH, Cheng JC, et al. Growth differentiation factor 8 suppresses cell proliferation by up-regulating CTGF expression in human granulosa cells. *Mol Cell Endocrinol*. 2016;422:9–17.

33. Winterhager E, Gellhaus A. The role of the CCN family of proteins in female reproduction. *Cell Mol Life Sci*. 2014;71(12):2299–2311.

34. Nagashima T, Kim J, Li Q, et al. Connective tissue growth factor is required for normal follicle development and ovulation. *Mol Endocrinol*. 2011;25(10):1740–1759.

35. Elliott CG, Forbes TL, Leask A, et al. Inflammatory microenvironment and tumor necrosis factor alpha as modulators of periostin and CCN2 expression in human non-healing skin wounds and dermal fibroblasts. *Matrix Biol*. 2015;43:71–84.

36. Fitzner B, Brock P, Nechutova H, et al. Inhibitory effects of interferon-gamma-on activation of rat pancreatic stellate cells are mediated by STAT1 and involve down-regulation of CTGF expression. *Cell Signal*. 2007;19(4):782–790.

37. Laug R, Fehrholz M, Schuttze N, et al. IFN-gamma and TNF-alpha synergize to inhibit CTGF expression in human lung endothelial cells. *PLoS One*. 2012;7(9):e45430.

38. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol*. 2016;16(10):626–638.

39. Straub RH. The complex role of estrogens in inflammation. *Endocr Rev*. 2007;28(5):521–574.

40. Karpuzoglu E, Phillips RA, Gogal RM, et al. Mitogen activated protein kinase (MAPK) mediates non-genomic pathway of estrogen in murine splenocytes: role of IL-27 but not IL-12. *Mol Immunol*. 2007;44(7):1808–1814.

41. Suzuki T, Yu HP, Hsieh YC, et al. Matrix metalloproteinase P450 gene (Cyp19) in mice and their ovarian and uterine response to 17-oestradiol. *J Endocrinol*. 2001;170(1):99–111.

42. Suzuki T, Yu HP, Hsieh YC, et al. Mitogen activated protein kinase (MAPK) mediates non-genomic pathway of estrogen on T cell cytokine production following trauma-hemorrhage. *Cytokine*. 2008;42(1):32–38.

43. Moullon VR. Sex hormones in acquired immunity and autoimmune disease. *Front Immunol*. 2018;9:2279.
43. Mohammad I, Starskaia I, Nagy T, et al. Estrogen receptor α contributes to T cell–mediated autoimmune inflammation by promoting T cell activation and proliferation. Sci Signal. 2018;11(526):eaap9415.

44. Tai P, Wang J, Jin H, et al. Induction of regulatory T cells by physiological level estrogen. J Cell Physiol. 2008;214(2):456–464.

45. Polanczyk MJ, Carson BD, Subramanian S, et al. Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol. 2004;173(4):2227–2230.

46. Vrachnis N, Zygouris D, Iliodromiti Z, et al. Probing the impact of sex steroids and menopause-related sex steroid deprivation on modulation of immune senescence. Maturitas. 2014;78(3):174–178.

47. Falorni A, Brozzetti A, Aglietti MC, et al. Progressive decline of residual follicle pool after clinical diagnosis of autoimmune ovarian insufficiency. Clin Endocrinol (Oxf). 2012;77(3):453–458.

48. La Marca A, Marzotti S, Brozzetti A, et al. Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. J Clin Endocrinol Metab. 2009;94(10):3816–3823.

49. Li D, Wang X, Dang Y, et al. lncRNA GCAT1 is involved in premature ovarian insufficiency by regulating p27 translation in GCs via competitive binding to PTBP1. Mol Ther Nucleic Acids. 2020;23:132–141.

50. Wang X, Zhang X, Dang Y, et al. Long noncoding RNA HCP5 participates in premature ovarian insufficiency by transcriptionally regulating MSH5 and DNA damage repair via YB1. Nucleic Acids Res. 2020;48(8):4480–4491.

51. Nishi Y, Yanase T, Mu Y, et al. Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology. 2001;142(1):437–445.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Jiao X, Zhang X, Li N, et al. Treg deficiency-mediated Th1 response causes human premature ovarian insufficiency through apoptosis and steroidogenesis dysfunction of granulosa cells. Clin Transl Med. 2021;11:e448. https://doi.org/10.1002/ctm2.448